Drug Profile
Isoglycyrrhizinate - Chia Tai Tianqing Pharmaceutical
Alternative Names: Ganmei; Magnesium isoglycyrrhizinate; Tianqing Ganmei; Tianqingganmei; Yigancaosuanmei ZhusheyeLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Developer Chia Tai Tianqing Pharmaceutical Group; Shanghai Jiao Tong University
- Class Anti-inflammatories; Hepatoprotectants; Saponins
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic hepatitis; Liver disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Liver-disorders (In volunteers) in China (IV, Infusion)
- 14 Apr 2016 Launched for Liver disorders and Chronic hepatitis in China (IV) before April 2016 (Chia Tai Tianqing Pharmaceutical Group website, April 2016)
- 14 Apr 2016 Adverse events data from a phase III trial in Liver disorders released by Chia Tai Tianqing Pharmaceutical Group (IV, Injection) (Chia Tai Tianqing Pharmaceutical Group website, April 2016)